California Cannabis Firm Aids Ethnobotanical Startup Neural Therapeutics' Market Debut

The move represents a key strategic step in the company's broader business plan.

Vertical Peak Holdings Inc., a British Columbia-based company focused on the cannabis industry, announced Tuesday that it is ready to finalize its proposed distribution of Neural Therapeutics Inc. shares to its shareholders.

The move, slated for May 23, represents a key strategic step in the company’s broader business plan.

Vertical Peak (CSE: MJMJ) (OTC: SPLIF), which develops and makes branded cannabis products, has a portfolio that includes flower, pre-rolls, vapes, edibles, and oil extracts for both medical and adult recreational use. The company operates under multiple licenses in California, which permit manufacturing, retail, and cultivation operations.

At the heart of Vertical Peak’s portfolio lie the OutCo and Thrive brands, which were added in 2021 following the acquisition of OutCo’s business.

Neural Therapeutics, the company whose shares are to be distributed, is an ethnobotanical drug discovery and development company. It focuses on developing products and conducting research with psychoactive plants, with its initial focus on a cactus known as San Pedro (Echinopsis pachanoi), which contains mescaline.

Vertical Peak clarified that the distribution is part of a previously announced plan of arrangement, in which shareholders who own Vertical Peak shares as of Friday, May 19 will be eligible for the distribution. The process will commence on the effective date, with an ex-dividend date set for Thursday.

Each Vertical Peak shareholder will receive a portion of Neural shares, directly proportional to their current Vertical Peak holdings. The company anticipates that each shareholder will receive approximately 0.013884682 of a Neural share for each lesser-value Vertical Peak share and about 0.13884682 of a Neural share for each higher-value Vertical Peak share.

Vertical Peak has established that it will not distribute fractional Neural shares; instead, any fractional shares will be rounded down to the nearest whole share. If rounding down would leave a shareholder with no Neural shares, they will receive one full share.

Neural Therapeutics also revealed its plans to list its shares on a Canadian stock exchange, which depends on the company meeting all listing requirements and gaining exchange approval.

Adam Jackson

Adam Jackson writes about the cannabis industry for the Green Market Report. He previously covered the Missouri Statehouse for the Columbia Missourian and has written for the Missouri Independent. He most recently covered retail, restaurants and other consumer companies for Bloomberg Business News. You can find him on Twitter at @adam_sjackson and email him at

Leave a Reply

Your email address will not be published. Required fields are marked *

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.

 Sign up

About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


Recent Tweets

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.